Speculation surrounds early end of ARBITER 6
10 July 2009
Alex Shimmings
Please Login to read the full article.
10 July 2009
Alex Shimmings
alex.shimmings@informa.com
The ARBITER 6 HALTS study comparing Merck/ Schering-Plough Pharmaceuticals' Zetia (ezetimibe) and Abbott's extended-release niacin product Niaspan has been stopped early.
The decision was taken by its independent steering committee following a prespecified, blinded interim analysis and...
Please Login to read the full article.
RELATED CONTENT
NEWS
- AIM-HIGH misses its mark, but hits Abbott and the "HDL hypothesis"
- FDA panel backs Merck's Vytorin in predialysis CKD, but rejects dialysis use
- Lilly Phase II data lifts lipid management CETP inhibitor arena
- Omthera trials fish oil pill Epanova with statins, hoping for 2012 filing in high TG
FEATURES
Other Informa Features
EVENTS
28 February 2012
Pestana Chelsea Bridge Hotel London
04 March 2012
The Marriott World Center, Orlando, Florida
26 March 2012
Copenhagen, Denmark
JOB OF THE WEEK
Promote your vacancy here
